Launch of new application enables global access to highly recognized solid tumor profiling assay

新应用程序的推出使全球能够获得高度认可的实体瘤分析

Boston, MA and Rolle, Switzerland [November 20, 2024] – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, announced the global launch of MSK-IMPACT® powered with SOPHiA DDM™ today from the Association for Molecular Pathology (AMP) Annual Meeting. This innovative solution provides organizations worldwide with the opportunity to benefit from Memorial Sloan Kettering Cancer Center (MSK)’s best-in-class comprehensive genomic profiling (CGP) application on the SOPHiA DDM™ Platform with high accuracy and efficiency..

马萨诸塞州波士顿和瑞士罗尔【2024年11月20日】–SOPHiA GENETICS（Nasdaq:SOPH）是数据驱动医学领域的云本地医疗技术领导者，今天在分子病理学协会（AMP）年会上宣布在全球推出以SOPHiA DDM™为动力的MSK-IMPACT®。这一创新的解决方案为世界各地的组织提供了机会，可以在SOPHiA DDM™平台上以高精度和高效率受益于Memorial Sloan Kettering癌症中心（MSK）一流的综合基因组分析（CGP）应用程序。。

“The launch of MSK-IMPACT® powered with SOPHiA DDM™ is another major milestone in our journey to expand access to precision oncology globally and demonstrates our commitment to democratizing data-driven medicine,” said Philippe Menu, M.D., PhD., Chief Product Officer and Chief Medical Officer, SOPHiA GENETICS.

医学博士Philippe Menu说：“以SOPHiA DDM™为动力的MSK-IMPACT®的推出是我们在全球范围内扩大精准肿瘤学获取途径的另一个重要里程碑，并证明了我们对数据驱动医学民主化的承诺。”。，SOPHiA GENETICS首席产品官兼首席医疗官。

“Following the successful launch of MSK-ACCESS® powered with SOPHiA DDM™ earlier this year, we are incredibly excited to further build on our excellent collaboration with MSK. Launching this application is a powerful step in our vision to decentralize access to advanced tumor profiling technologies, making these capabilities more widely available, especially in underserved populations.” .

“在今年早些时候成功推出了以SOPHiA DDM™为动力的MSK-ACCESS®之后，我们非常高兴能够在与MSK的出色合作基础上进一步发展。启动此应用程序是我们实现分散访问先进肿瘤分析技术的愿景的有力一步，使这些功能更广泛地可用，特别是在服务不足的人群中。”。

Kojo S. J. Elenitoba-Johnson, M.D., Chair of the Department of Pathology and Lab Medicine at MSK, added, “We share a vision with SOPHiA GENETICS to advance precision medicine and to make our leading tests more accessible to patients around the world.”

MSK病理学和实验室医学系主任Kojo S.J.Elenitoba Johnson医学博士补充道：“我们与SOPHiA GENETICS有着共同的愿景，以推进精准医学，并使我们领先的测试更容易为世界各地的患者所接受。”

Through MSK-IMPACT® powered with SOPHiA DDM™, organizations can process more precise oncology analysis by enhancing the accuracy of somatic mutation detection. The matched tumor-normal analysis approach allows clinicians and researchers to detect somatic mutations more confidently, minimizing the risk of misclassifying germline variants as tumor-specific.

通过以SOPHiA DDM™为动力的MSK-IMPACT®，组织可以通过提高体细胞突变检测的准确性来处理更精确的肿瘤学分析。匹配的肿瘤正常分析方法使临床医生和研究人员能够更自信地检测体细胞突变，从而最大程度地降低将种系变异错误分类为肿瘤特异性的风险。

Additionally, institutions benefit from the global collective intelligence created by SOPHiA GENETICS’ network, allowing users to contribute to and draw from a continuously evolving base of real-world data and insights from diverse populations..

此外，各机构还受益于索菲亚遗传学网络创建的全球集体智慧，使用户可以为不断发展的现实世界数据和来自不同人群的见解做出贡献并从中汲取经验。。

SOFIVA GENOMICS, a leading molecular diagnostics company in Taiwan, is among the first to adopt this application. The company initially partnered with SOPHiA GENETICS in 2022 to utilize the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution. Now, SOFIVA GENOMICS is expanding its tumor profiling capabilities by adding MSK-IMPACT® powered with SOPHiA DDM™ alongside the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™.

台湾领先的分子诊断公司SOFIVA GENOMICS是首批采用此应用程序的公司之一。该公司最初于2022年与SOPHiA GENETICS合作，利用SOPHiA DDM™同源重组缺陷（HRD）解决方案。现在，SOFIVA GENOMICS正在通过添加由SOPHiA DDM™供电的MSK-IMPACT®以及由SOPHiA DDM™供电的液体活检测试MSK-ACCESS®来扩展其肿瘤分析功能。

.

.

Chia-Cheng Hung, General Manager, SOFIVA GENOMICS, commented, “Our partnership with SOPHiA GENETICS has greatly enhanced our ability to provide localized, highly accurate genomic testing. Access to this advanced technology enables us to bring advanced, trusted capabilities and further our progress on cancer research in Taiwan.”.

SOFIVA GENOMICS总经理Chia Cheng Hung评论道：“我们与SOPHiA GENETICS的合作大大增强了我们提供本地化，高度准确的基因组测试的能力。获得这项先进技术使我们能够带来先进，可信的能力，并进一步推动我们在台湾癌症研究方面的进展。”。

MSK-IMPACT® powered with SOPHiA DDM™ enables a more efficient workflow, with the entire process from DNA extraction to final report taking approximately five days. Clinicians and researchers benefit from access to OncoKB™, MSK’s Precision Oncology Knowledge Base, which further enhances the interpretive power of the SOPHiA DDM™ analysis through data-driven, actionable insights.

采用SOPHiA DDM™的MSK-IMPACT®实现了更高效的工作流程，从DNA提取到最终报告的整个过程大约需要五天。临床医生和研究人员受益于访问OncoKB™，这是MSK的精确肿瘤学知识库，它通过数据驱动的可行见解进一步增强了SOPHiA DDM™分析的解释能力。

In-house analytical validation results for MSK-IMPACT® powered with SOPHiA DDM™ showed high concordance to the single-site MSK-IMPACT® test, achieving:.

使用SOPHiA DDM™供电的MSK-IMPACT®的内部分析验证结果与单点MSK-IMPACT®测试高度一致，达到：。

99.3% positive percent agreement (PPA) for SNV/Indel detection

SNV/Indel检测的99.3%阳性百分比协议（PPA）

94.6%  PPA for copy number variant (CNV) detection

94.6%的PPA用于拷贝数变异（CNV）检测

99.4% overall percent agreement (OPA) for microsatellite instability (MSI) detection

微卫星不稳定性（MSI）检测的99.4%总体百分比一致性（OPA）

98.8% OPA for tumor mutational burden (TMB) detection.

98.8%的OPA用于肿瘤突变负荷（TMB）检测。

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com, or connect on LinkedIn.

有关SOPHiA GENETICS的更多信息，请访问SOPHiAGENETICS.com，或连接LinkedIn。

About SOPHiA GENETICS

关于SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.

SOPHiA GENETICS（Nasdaq:SOPH）是一家云本地医疗保健技术公司，其使命是通过在全球范围内扩展数据驱动医学的访问来改变患者护理。它是SOPHiA DDM™平台的创建者，该平台分析复杂的基因组和多模式数据，并为医院，实验室和生物制药机构的广泛全球网络生成实时可行的见解。

For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn..

有关更多信息，请访问SOPHiAGENETICS.com并通过LinkedIn与我们联系。。

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use.

SOPHiA GENETICS产品仅供研究使用，除非另有说明，否则不得用于诊断程序。本新闻稿中的信息是关于不同国家可能提供或可能不提供的产品，如果适用，可能已经或可能尚未获得政府监管机构对不同使用适应症的批准或市场许可。

Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. Concordance results based on analytic assessment of RUO products..

请联系support@sophiagenetics.com获取您居住国家的适当产品信息。。。

Memorial Sloan Kettering (MSK) has institutional financial interests related to SOPHiA GENETICS.

Memorial Sloan Kettering（MSK）拥有与SOPHiA GENETICS相关的机构财务利益。

SOPHiA GENETICS Forward-Looking Statements:This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements.

SOPHiA GENETICS前瞻性声明：本新闻稿包含构成前瞻性声明的声明。除本新闻稿中包含的历史事实声明外，所有声明均为前瞻性声明，包括关于我们未来经营成果和财务状况、经营战略、产品和技术以及未来经营管理计划和目标的声明。

Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S.

。此类报表存在风险和不确定性，由于各种因素，包括我们向美国提交的文件中所述的因素，实际结果可能与前瞻性报表中明示或暗示的结果存在重大差异。

Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law.

证券交易委员会。不能保证将来会取得这样的结果。本新闻稿中包含的此类前瞻性声明仅在本新闻稿发布之日有效。除非适用法律要求，否则我们明确否认有义务或承诺更新本新闻稿中包含的前瞻性声明，以反映我们预期的任何变化或此类声明所依据的事件、条件或情况的任何变化。

No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements..

对于任何此类前瞻性陈述的准确性，不作任何陈述或保证（明示或暗示）。。

Media Contact:Kelly Katapodismedia@sophiagenetics.com

媒体联系人：KellyKatapodismedia@sophiagenetics.com